|Bid||225.53 x 800|
|Ask||226.40 x 800|
|Day's Range||221.53 - 227.80|
|52 Week Range||216.12 - 388.67|
|Beta (3Y Monthly)||1.85|
|PE Ratio (TTM)||10.49|
|Earnings Date||Apr 24, 2019|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||261.19|
Roche's (RHHBY) performance in the first quarter of 2019 is driven by solid strength of new drugs, which more than offset competition from biosimilars.
Biogen (BIIB) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Adults with later-onset spinal muscular atrophy (SMA) who are not being treated show increased rates of hospital admissions, clinical interventions and mortality, indicating an.
A German artificial-intelligence firm had come to a different conclusion. Innoplexus AG, a closely held company based in the outskirts of Frankfurt, uses an algorithm to analyze pharma companies’ drug pipelines that it says takes more data and context into account than any other tool. Its assessment of Biogen’s aducanumab gave about a 70 percent to 90 percent chance that the trial would miss its goal.
Want to participate in a research study? Help shape the future of investing tools and earn a $60 gift card! This article is written for those who want to get better at using price to earnings ratios (P/E ratios). To keep it prac...
Biogen Inc should slash the price of its spinal muscular atrophy (SMA) drug, and the $4 million to $5 million Novartis has said its experimental gene therapy for the disease is worth is excessive, an independent U.S. organization that reviews the value of medical treatments said on Wednesday. Assessments by the nonprofit Institute for Clinical and Economic Review (ICER) have become increasingly influential in U.S. drug pricing and are taken into consideration by health insurers and pharmacy benefit managers making decisions about payments and patient access to treatments. Boston-based ICER has been looking at Biogen's Spinraza and Novartis' Zolgensma since last year.
Biogen (BIIB) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.
Merck KaaA (MKGAF) announces approval of Mavenclad in the United States as a treatment for multiple sclerosis. The drug is already approved in other countries including Europe.
Biogen threw in the towel with once-promising Alzheimer's disease drug aducanumab. But these three late-stage pipeline candidates could potentially still emerge as winners.
The biotech space is witnessing a rally so far in 2019. Here we discuss four stocks that are likely to witness a continuation of the uptrend going ahead.
Biogen's pipeline pitfall casts doubt on its strategy. Meanwhile, a shareholder revolt threatens Bristol-Myers' tie-up with Celgene.
What Analysts Are Recommending for These Biotech Giants in March(Continued from Prior Part)Analysts’ recommendations and target priceWall Street analysts expect a potential upside of 13.56% for Biogen (BIIB) based on its closing price on March
The Swiss pharmaceutical company halted its trial of aducanumab because it wasn't helping patients. But it could still help researchers.